about
Novel technologies and emerging biomarkers for personalized cancer immunotherapyVaccines, Adjuvants, and Dendritic Cell Activators--Current Status and Future Challenges.Recent advances in T-cell engineering for use in immunotherapyTumor neoantigens: building a framework for personalized cancer immunotherapyA Pan-Cancer Catalogue of Cancer Driver Protein Interaction InterfacesSystematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia.High sensitivity of cancer exome-based CD8 T cell neo-antigen identificationGenomic and bioinformatic profiling of mutational neoepitopes reveals new rules to predict anticancer immunogenicity.Neoantigens in cancer immunotherapy.Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens.A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell linesSystematic transcriptome analysis reveals tumor-specific isoforms for ovarian cancer diagnosis and therapyStrong spontaneous tumor neoantigen responses induced by a natural human carcinogen.Haematological malignancies: at the forefront of immunotherapeutic innovation.Low Mutation Burden in Ovarian Cancer May Limit the Utility of Neoantigen-Targeted Vaccines.The Value of Online Algorithms to Predict T-Cell Ligands Created by Genetic Variants.Immunotherapy for neuro-oncology: the critical rationale for combinatorial therapy.TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expressionTargeting the undruggable: immunotherapy meets personalized oncology in the genomic era.Targeting human melanoma neoantigens by T cell receptor gene therapyEnrichment and Expansion with Nanoscale Artificial Antigen Presenting Cells for Adoptive Immunotherapy.Identification of immunotherapeutic targets by genomic profiling of rectal NET metastases.Can we predict mutant neoepitopes in human cancers for patient-specific vaccine therapy?Somatically mutated tumor antigens in the quest for a more efficacious patient-oriented immunotherapy of cancer.Targeting cancer-specific mutations by T cell receptor gene therapy.Personalized cancer immunotherapy using Systems Medicine approaches.The neoepitope landscape in pediatric cancers.Tools to define the melanoma-associated immunopeptidome.HLA class I loss in metachronous metastases prevents continuous T cell recognition of mutated neoantigens in a human melanoma model.The Role of Neoantigens in Naturally Occurring and Therapeutically Induced Immune Responses to Cancer.Neoantigens in immunotherapy and personalized vaccines: Implications for head and neck squamous cell carcinoma.Challenges in vaccine therapy in hematological malignancies and strategies to overcome them.Genomic Approaches to Understanding Response and Resistance to Immunotherapy.Novel vaccines for glioblastoma: clinical update and perspective.Targeting neoantigens to augment antitumour immunity.Resistance to immunotherapy: clouds in a bright sky.Antigen Discovery and Therapeutic Targeting in Hematologic Malignancies.In silico and cell-based analyses reveal strong divergence between prediction and observation of T-cell-recognized tumor antigen T-cell epitopes.Clinical responses to adoptive T-cell transfer can be modeled in an autologous immune-humanized mouse model.Personal neoantigen cancer vaccines: The momentum builds.
P2860
Q26770780-F8B1AF29-20F3-44DE-B968-D4D605238536Q26796314-A098B51E-1918-48FA-BFCA-58D8D5FC59A3Q28080312-BC538886-6AD7-4A71-A3F0-316610C64CDEQ28082704-2A10F1EB-A64A-45B4-B0AA-AB0F0E7ED6C6Q28550391-375FDAE3-7F3C-4F22-82AB-8982B3426628Q33917224-55B1533B-8674-444F-A855-36AD12FD8266Q33930588-2FF82AC1-F8F5-4360-97B4-7E9E44990938Q34375163-737F7EBB-43F4-47B9-B609-8E3B5A45CE27Q34470074-5EF6A05E-33DB-4ABB-9B3C-595356A60481Q34788858-CB69EFD8-A7FC-4D53-ADE1-8A61B8CB5925Q35626593-DDD6540C-6E52-4792-88E6-44DBAEF9DE95Q35740435-8ED165D7-4AC4-482E-AF18-2A779C901804Q35799065-23075E19-5549-4A26-A7D3-276D9D90E2E4Q35880618-999AE60B-84DB-47E7-8874-B736A8EF3DAEQ36021163-20728E35-921B-4178-A1CC-58BC951F12E5Q36129950-94C39970-E840-40EF-B7BC-BBCBDDCFBC6AQ36224057-41BD2150-8E92-4E4D-BFBB-F7FEE133FE12Q36301828-A891AA3B-2BDD-4B73-8742-2FAA8B876AD3Q36316627-D28C22CB-7197-4AD8-B91E-86660485AF16Q36618620-F2BE5E89-65B4-4EC3-9423-04A02D2CB72EQ37370230-B8DD2D84-BD65-4BAA-BF08-11ECC854CAF4Q37477282-2850B7E5-47A6-4195-A178-9A0A644D5435Q38209294-7639A808-89A6-455B-983E-5980112D6D97Q38244094-955ED427-0122-45EA-B604-B6555F8E8DA5Q38366556-CBF8A46A-0CC9-403F-AD6F-22AE62F402DDQ38547040-4595772B-D486-4406-9ECB-259CC4079B3AQ38601828-3047BEF1-FA06-4D83-83C0-285F38C68859Q38650013-732E4758-0124-4398-8594-F0D5D562A34EQ38706874-B7457F02-9943-488A-966E-DCDAB9FCE30DQ38753386-506538D2-BB62-4916-92F3-C16C8D0C2311Q38810264-0B47C0D8-2911-4CB1-8BDC-E912525CB6CBQ38843235-1E88E69B-BAAE-4891-AFBD-7E347FAD9A64Q38971262-FB127105-693A-4022-BD00-5FECF7E7254FQ39043417-47E76FD0-53FB-4ADB-94A9-4382D8C7DDD7Q39149196-481B2285-CC38-49C9-8B0F-E03B9350A797Q39236810-F9D2E2E0-E1A0-44BD-92BA-A9CC35F9C3C8Q39243052-6CF599CA-E95F-4E84-AA93-A46BB1129E4DQ40188864-4CE0BC49-CE84-48EE-9369-E00D3B8DCD59Q41915301-E3810CCE-148D-4BBC-9BC6-302EBBC7E3F5Q41985178-95EFCA42-9E15-4FCE-A0DE-16854250B0DA
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
HLA-binding properties of tumor neoepitopes in humans.
@en
type
label
HLA-binding properties of tumor neoepitopes in humans.
@en
prefLabel
HLA-binding properties of tumor neoepitopes in humans.
@en
P2093
P2860
P1476
HLA-binding properties of tumor neoepitopes in humans.
@en
P2093
Catherine J Wu
Edward F Fritsch
Mohini Rajasagi
Patrick A Ott
P2860
P304
P356
10.1158/2326-6066.CIR-13-0227
P577
2014-03-03T00:00:00Z